Anti-Nociceptin Receptor antibody
Specifications
| Product Cat#: | AB-06-3166 |
| Product type: | Primary antibody |
| Antigen: | Nociceptin receptor |
| Immunogen: | KLH conjugated synthetic peptide derived from human Nociceptin receptor 1-47/370 |
| Species immunized: | Rabbit |
| Isotype: | IgG |
| Applications: | Western Blot (1:200-1:2000); Immunohistochemistry-Paraffin (1:500-800) |
| Reactivity: | Human, Mouse, Rat, Dog, Pig, Cow, Horse, Guinea Pig |
| Clonality (clone number): | Polyclonal |
| Form: | Liquid |
| Buffer: | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Concentration: | 1 mg/ml |
| Purity: | Protein A affinity purified |
| Storage: | Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles. |
| Alternative names: | H.sapiens mRNA for ORL1 receptor |
| Kappa type 3 opioid receptor | |
| KOR 3 | |
| KOR-3 | |
| KOR3 | |
| LC132 receptor like | |
| MGC34578 | |
| Nociceptin receptor | |
| NOCIR | |
| OOR | |
| Opiate receptor like 1 | |
| Opiod receptor like 1 | |
| Oprl1 | |
| OPRX_HUMAN | |
| ORL1 |
Show More
Target information
G-protein coupled opioid receptor that functions as receptor for the endogenous neuropeptide nociceptin. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling via G proteins mediates inhibition of adenylate cyclase activity and calcium channel activity. Arrestins modulate signaling via G proteins and mediate the activation of alternative signaling pathways that lead to the activation of MAP kinases. Plays a role in modulating nociception and the perception of pain. Plays a role in the regulation of locomotor activity by the neuropeptide nociceptin.
Provider
Erpantech Laboratory
